Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether expansion of NK cells with IL-15 and nicotinamide would improve responses in patients with NHL and MM.

In an analysis of more than 10,000 cancer clinical trials, less than half had results reported within 1 year of trial completion.

Annual follow-up with ¹⁸FDG-PET/CT may improve survival, as compared to conventional follow-up, in patients with head and neck cancer.

Bevacizumab can reduce the risk of progression in patients with ovarian cancer for about 1 year after treatment initiation, but discontinuing the drug increases the risk of progression, researchers found.

Patients with node-positive bladder cancer without distant metastases have similar outcomes with radical dose radiotherapy as with radical cystectomy, a study suggests.

Engaging in vigorous physical activity for 3 to 4 minutes per day is associated with a decrease in the risk of cancer among adults who typically don’t exercise, new research suggests.

Patients with TP53 wild-type endometrial cancer had longer progression-free survival when they received selinexor maintenance in a phase 3 trial.

Changing trastuzumab dosing strategies for breast cancer treatment can reduce greenhouse gas emissions, a new study suggests.

Patients exposed to wildfire after curative-intent surgery for non-small cell lung cancer may have a higher risk of death than patients unexposed to wildfire.

Combination treatment with camrelizumab and rivoceranib is more effective than sorafenib monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma, phase 3 data suggest.